FDA approves a new blood test to detect signs of Alzheimer’s

Live updates

1. 20d ago

   FDA Approves Blood Test to Detect Alzheimer's Signs

   The US FDA has approved a blood test developed by Roche and Eli Lilly to detect signs of Alzheimer's disease. The test, called Elecsys pTau-217, will be available through Labcorp and can be used in both primary and specialty care settings. This approval provides a new tool for diagnosing Alzheimer's, a disease that affects millions of people worldwide.

   Why it matters

   Alzheimer's disease is a progressive neurological disorder that can cause memory loss, cognitive decline, and eventually death. Early detection and diagnosis are crucial for managing the disease and developing effective treatment plans. The approved blood test is expected to improve the diagnosis and monitoring of Alzheimer's patients.

   What is confirmed

   • The FDA approved the Elecsys pTau-217 blood test developed by Roche and Eli Lilly.
   • The test will be available through Labcorp in primary and specialty care settings.
   • The Elecsys pTau-217 test aids in the evaluation for Alzheimer's disease.

   What to watch next

   • Availability and pricing of the Elecsys pTau-217 test
   • Clinical trials and studies on the test's efficacy and accuracy
   • Potential impact on Alzheimer's disease diagnosis and treatment
   Sources used for this update (8)

   1. WSJ — FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
   2. WashU Medicine — FDA clears blood test to aid evaluation for Alzheimer’s disease
   3. The Washington Post — FDA approves a new blood test to detect signs of Alzheimer’s
   4. The Hill — FDA approves new blood test for Alzheimer’s disease
   5. CNN — Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance
   6. WTHR — FDA approves new Alzheimer’s blood test from Roche, Eli Lilly
   7. MedTech Dive — Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
   8. www.pharmabiz.com — Labcorp to offer Elecsys pTau-217 test, an US FDA-cleared blood test to detect Alzheimer's disease pathology in both primary and specialty care settings
   confidence 100%